Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637481 · ClinicalTrials.gov registry record · Phase 1
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00637481: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00637481 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00637481, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
Chemoprevention is the use of certain drugs to keep cancer from forming. The use of atorvastatin (Lipitor) may prevent breast cancer. This randomized phase I trial is studying the best dose of atorvastatin in preventing breast cancer in women at increased risk for breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG atorvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637481
The ClinicalTrials.gov registry entry for NCT00637481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00637481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637481 about?
NCT00637481 is a clinical study titled "A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer". Chemoprevention is the use of certain drugs to keep cancer from forming. The use of atorvastatin (Lipitor) may prevent breast cancer. This randomized phase I trial is studying the best dose of atorvastatin in preventing breast cancer in women at increased risk for breast cancer.
What is the current status of trial NCT00637481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2008-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00637481?
The interventions under investigation include: laboratory biomarker analysis (OTHER), atorvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00637481?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.